Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424814 | 0.87 | L3MBTL1 (0.48) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL30546511 | 0.87 | L3MBTL1 (0.48) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL17078010 | 0.85 | NR4A2 (0.47) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL21962894 | 0.85 | CA2 (0.61) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL21488190 | 0.84 | NR1H2 (0.38) | CA1CA2CA9SMN1; SMN2ALDH1A1 | |
| SCHEMBL17494875 | 0.84 | SMN1; SMN2 (0.46) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL3472808 | 0.83 | ALDH1A1 (0.49) | CA1CA2CA9KDM4ESMN1; SMN2 | |
| SCHEMBL22010261 | 0.83 | CA2 (0.50) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL1368657 | 0.83 | KDM4E (0.45) | NR4A2CA1CA2CA9CA5A | |
| SCHEMBL29295507 | 0.81 | NR4A2 (0.43) | NR4A2CA1CA2CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| EP-4353712-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2024-04-17 | — | — | EP | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | NR4A2 36/4885CA1 4755/4885CA2 4763/4885 |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | NR4A2 2179/4885CA1 3615/4885CA2 1285/4885 |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | NR4A2 30/4885CA1 3256/4885CA2 804/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | NR4A2 41/4885CA1 4739/4885CA2 4776/4885 |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | NR4A2 2179/4885CA1 3615/4885CA2 1285/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | NR4A2 36/4885CA1 4773/4885CA2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.